Alluvi, formerly BI 4744, presents a promising advance in weight loss care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates impressive results in clinical https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/